The ITRT's scientific track record, published and cited in the world's leading international scientific journals.

View publications
Group 1034 1

We have a consolidated scientific track record with international recognition in advanced cell therapy medicinal products using cultured mesenchymal cells (CMC).

This work has resulted in publications in international journals indexed in PubMed/MEDLINE, Scopus and Web of Science, with over 1,000 cumulative citations in the specialized scientific literature.

What scientific evidence supports ITRT’s cultured mesenchymal cell (CMC) medicines?

ITRT’s evidence comes from clinical trials and clinical series published in peer-reviewed journals, mainly in knee osteoarthritis, patellar tendinopathy, lumbar degenerative disc disease and atrophic non-union. Most are small phase I/II studies: they show a good safety profile and clinical and structural improvements on imaging, but their results cannot be extrapolated to every patient or to other indications.

Author: Dr Robert Soler, Medical Director of ITRT. Updated 12 October 2026.

Published studies by indication

IndicationStudyDesign and patientsMain findingRegistration
Chronic patellar tendinopathyRodas et al., Am J Sports Med, 2021 (PMID 33783227)Phase 1/2, randomized, double-blind, active control; 20 patientsAt 6 months, pain and function improved in both groups with no difference between them; tendon structure improved significantly more with CMC on ultrasound and MRIEudraCT 2016-001262-28; NCT03454737
Chronic patellar tendinopathy (follow-up)Soler et al., Orthop J Sports Med, 2023 (PMID 37711505)12-month follow-up of the 20 patients, all treated with CMCClinical improvement and improved tendon structure on MRI maintained; no adverse eventsSame trial
Chronic patellar tendinopathy (secondary analysis)Ortega-Cebrián et al., Biomedicines, 2024 (PMID 39062172)Secondary analysis of the same trial using ultrasound tissue characterization (UTC); 20 male patientsBetter structural organization of the tendon in the CMC group at 3, 6 and 12 monthsSame trial
Knee osteoarthritisOrozco et al., Transplantation, 2013 (PMID 23680930)Uncontrolled pilot study; 12 patients, autologous CMCSafety and feasibility confirmed; improvement in pain and function at one year; improved cartilage quality on MRI (T2 mapping) in 11 of 12 patientsNot stated in the abstract
Knee osteoarthritisVega et al., Transplantation, 2015 (PMID 25822648)Randomized; 30 patients, allogeneic CMC versus hyaluronic acidSignificant improvement in pain and function indices versus the control group; improved cartilage quality on T2 mappingEudraCT 2011-005321-51; NCT01586312
Knee osteoarthritisSoler et al., Knee, 2016 (PMID 26783191)Open-label, single-arm phase I-II; 15 patientsWell tolerated; sustained pain reduction; signs of cartilage repair on T2 mapping at 12 monthsNot stated in the abstract
Lumbar degenerative disc diseaseOrozco et al., Transplantation, 2011 (PMID 21792091)Uncontrolled pilot study; 10 patientsImprovement in pain and disability; increased disc water content at 12 months, without recovery of disc heightNot stated in the abstract
Atrophic non-union of long bonesOrozco Delclós et al., J Transl Med, 2024 (PMID 38789992)Open-label, multicenter phase 2; 12 patients, adipose-derived CMC combined with a biomaterialBone healing in 10 of 12 cases (83%); two procedure-related adverse events, in the same patientEudraCT 2013-000930-37; NCT02483364
Chronic Achilles tendon ruptureSoler-Rich et al., J Orthop Sports Med, 2026 (DOI 10.26502/josm.511500254)Uncontrolled case series; 6 patients, minimum follow-up 24 monthsWell tolerated; improvement in pain and function; structural tendon changes on MRINot stated

What does this evidence show and where are its limits?

Taken together, the published studies describe a favorable safety profile, clinical improvements and structural changes measurable on imaging in several indications. At the same time, most are small, phase I/II or uncontrolled studies, and in the only controlled tendon trial the improvement in pain and function at six months did not differ from the control group: the difference lay in tendon structure. An improvement on MRI or ultrasound does not, on its own, mean the tissue is identical to the original. For these reasons the results cannot be extrapolated to every patient or to other injuries.

Where can the trials be consulted?

Studies with a registration number can be looked up in the EU clinical trials register (EudraCT, replaced by CTIS for new trials) and on ClinicalTrials.gov; the publications can be found on PubMed through their PMID. A trial being authorized and registered means it was carried out under regulatory and ethics oversight, not that the medicine holds a marketing authorization.

See also: What are cultured mesenchymal cells (CMC)? · Which cell-based treatments can be considered legal and regenerative?

Featured Article — New Publication 2026

New Article

First prospective series on chronic Achilles tendon rupture treated with autologous cultured mesenchymal cells

Ex Vivo Culture-Expanded Autologous Bone Marrow-Derived Mesenchymal Stem Cells (aBM-MSC) for Treatment of Chronic Achilles Tendon Rupture: A Prospective Series

A prospective series of patients with chronic Achilles tendon rupture treated with ex vivo expanded autologous cultured mesenchymal cells (CMC). The study provides the first published data on the use of this advanced cell therapy medicinal product in this indication.

Knee Osteoarthritis

First clinical demonstration of safety and functional improvement with autologous cultured mesenchymal cells

Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study

A pilot trial in 12 patients with knee osteoarthritis treated with an advanced cell therapy medicinal product based on autologous bone marrow-derived cultured mesenchymal cells (CMC). The study confirmed the safety of the procedure and showed clinical improvement at 12 months, with MRI findings compatible with changes in articular cartilage.

Two-year sustained results: clinical benefit persists beyond the first year

Treatment of knee osteoarthritis with autologous mesenchymal stem cells: two-year follow-up results

The 24-month follow-up of the pilot trial confirmed that improvements obtained with autologous cultured mesenchymal cells (CMC) were maintained over time. Patients preserved improvements in pain and functional capacity without further interventions, supporting the hypothesis of a sustained regenerative effect.

First randomized controlled trial with allogeneic CMC versus hyaluronic acid as control

Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial

This multicenter trial compared allogeneic cultured mesenchymal cells (donor-derived) with hyaluronic acid in 30 patients with moderate knee osteoarthritis. Results showed significantly superior clinical improvement in the CMC group, with a favorable safety profile, opening the path to the use of allogeneic advanced cell therapy medicinal products.

Series of 50 patients with radiological evidence of cartilage regeneration at one year

Treatment of Knee Osteoarthritis with Autologous Expanded Bone Marrow Mesenchymal Stem Cells: 50 Cases Clinical and MRI Results at One Year Follow-Up

With the largest published series at that time, we documented clinical and MRI results in 50 patients treated with autologous CMC expanded in a GMP cleanroom, in collaboration with IBGM. Findings showed consistent functional improvement and MRI signal changes compatible with articular cartilage regeneration at one year of follow-up.

Final results of the phase I/II trial: confirmed safety and suggested cartilage regeneration

Final results of a phase I-II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration

The publication of the final results of the phase I-II trial, with Dr. Soler as first author, closed the knee osteoarthritis series we initiated in 2013. The study confirmed the long-term safety of the advanced cell therapy medicinal product and provided imaging findings consistent with cartilage regeneration.

Patellar Tendinopathy

Design and protocol of a double-blind clinical trial comparing CMC versus PRP in patellar tendon

Autologous bone marrow expanded mesenchymal stem cells in patellar tendinopathy: protocol for a phase I/II, single-center, randomized with active control PRP, double-blinded clinical trial

In collaboration with the FC Barcelona Clinic and Hospital Dexeus, we published the complete protocol of the phase I/II trial comparing autologous cultured mesenchymal cells with platelet-rich plasma (PRP) in patients with severe chronic patellar tendinopathy. The double-blind design with active control constitutes one of the most rigorous methodological standards in clinical research involving biological treatments.

At six months, CMC patients show clinical and structural improvements in severe chronic patellar tendinopathy

Effect of Autologous Expanded Bone Marrow Mesenchymal Stem Cells or Leukocyte-Poor Platelet-Rich Plasma in Chronic Patellar Tendinopathy (With Gap >3 mm): Preliminary Outcomes After 6 Months of a Double-Blind, Randomized, Prospective Study

Preliminary results at 6 months of the double-blind trial documented clinical improvements and structural changes in the patellar tendon in patients treated with autologous CMC, particularly in tendons with partial rupture greater than 3 mm. The findings provided the first evidence of structural changes in the tendon documented through imaging techniques with this type of medicinal product.

Final 12-month results: demonstrated safety and sustained efficacy with CMC in tendon

Safety and Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Patellar Tendinopathy (With Gap >3 mm) in Patients: 12-Month Follow-up Results of a Phase 1/2 Clinical Trial

With Dr. Soler as first author, we present the complete results of the phase 1/2 trial at 12 months of follow-up. The study confirmed the safety profile of the advanced cell therapy medicinal product and documented sustained clinical benefits in patients with chronic patellar tendinopathy who had not responded to previous treatments.

Structural analysis of the tendon: CMC induces measurable tissue changes compared to PRP

Evaluation of Patellar Tendon Structural Changes following Biological Treatments: Secondary Analysis of Double Blinded Clinical Trial of Bone Marrow Mesenchymal Stromal Cells and Leukocyte-Poor Platelet-Rich Plasma

A secondary analysis of the double-blind trial evaluated structural changes in the patellar tendon using imaging techniques in both treatment groups. Results showed that CMC produced more significant tissue modifications than PRP, providing objective evidence of structural regeneration beyond subjective clinical improvement.

Lumbar Degenerative Disc Disease

First published clinical evidence on lumbar intervertebral disc regeneration with autologous CMC

Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study

We published the results of the first pilot trial demonstrating the feasibility and safety of treating degenerative intervertebral disc disease with autologous cultured mesenchymal cells. Follow-up MRI scans showed signs of disc rehydration, a marker of structural regeneration, in the treated patients.

Xerostomia

First publication on the use of CMC in post-radiotherapy xerostomia

Treatment with mesenchymal stem cells for xerostomia: A new paradigm in cell therapy

Our team published a first scientific communication on the use of cultured mesenchymal cells (CMC) in post-radiotherapy xerostomia. The work proposed an approach based on glandular regeneration, differentiated from conventional symptomatic treatments.

Muscle Injury

Evidence on PRP in muscle rupture with double-blind, placebo-controlled design and Cochrane methodological endorsement

Efficacy of autologous Platelet-Rich Plasma for treatment of muscle rupture with hematoma: a multicentre, randomized, double-blind, placebo-controlled clinical trial

In collaboration with Cochrane Spain, the FC Barcelona Clinic and the CAR, we documented evidence on the efficacy of autologous platelet-rich plasma in muscle ruptures with hematoma. The double-blind, placebo-controlled design represents a level of methodological rigour uncommon in biological treatments for acute sports injuries.

Atrophic Non-Union

Safety and bone consolidation demonstrated with adipose tissue-derived CMC in non-consolidated fractures

Efficacy and safety of autologous or allogeneic mesenchymal stromal cells from adult adipose tissue expanded and combined with tricalcium phosphate biomaterial for the surgical treatment of atrophic nonunion of long bones: a phase II clinical trial

We published the results of a multicenter phase II trial in atrophic non-union of long bones. The study demonstrated a favorable safety profile and clinically relevant bone consolidation outcomes with mesenchymal cells expanded from adipose tissue combined with tricalcium phosphate.

Scientific Track Record in Figures

14 publications

in international peer-reviewed scientific journals

+1,000 citations

accumulated in the specialized scientific literature

6 pathologies

 with published evidence: knee osteoarthritis, patellar tendinopathy, lumbar disc disease, xerostomia, muscle injury and atrophic non-union

23 trials

14 of them authorized clinical trials in patients

Collaborating institutions

images 2 1 3210 1
logo color 1 334 1
logoIdiPAZ 1 329 1
Screenshot 2026 03 13 104054 1 345 1
Logo verde 1 376 1
Logo Vision de las Americas f 1 364 1

Regulated Medicines, Verifiable Evidence

Publications in international peer-reviewed journals and accumulated citations are an objective way to validate the strength, visibility and impact of a scientific track record.

More than 20 years of clinical research and published scientific evidence in advanced cell therapy medicinal products with CMC.

f792ab52dc33fee9c4dd824786e8bac9ff3a5b99 scaled
We develop advanced cell therapy medicinal products manufactured in a GMP clean room, with individual AEMPS authorization and independent ethical review by CEIm, with evidence of structural regeneration demonstrated by imaging in musculoskeletal, disc and glandular pathologies.
Advanced cell therapy medicinal products using cultured mesenchymal cells (CMC) require medical prescription and individual authorization from the AEMPS. This content is for informational purposes only and does not replace medical advice.